Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Secures $7.5M in Revolving Credit

NEW YORK, Dec. 9 (GenomeWeb News) - Transgenomic said today that it has entered into an agreement for up to $7.5 million in a revolving line of credit with Laurus Master Fund.

Transgenomic said it would have access to the funds based on eligible accounts receivable and inventory balances. The arrangement replaces a previous $5.0 million line of credit from a commercial bank that had a higher interest rate, the company said.

Under the terms of the agreement, Transgenomic issued warrants to Laurus Funds to acquire up to 550,000 shares of its stock at a price based on a premium to the average trading price of its common stock for ten trading days prior to execution of the agreement.

In August, Transgenomic raised $4.5 million in a private placement with a number of investors.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.